Cost effectiveness analysis of etanercept versus infliximab in the treatment of rheumatoid arthritis patients

被引：0

作者：

Malone, DC

Ortmeier, BG

机构：

[1] Univ Arizona, Coll Pharm, Tucson, AZ 85721 USA

[2] Amgen Corp, Reg Med Liaison, Thousand Oaks, CA 91320 USA

来源：

ANNALS OF THE RHEUMATIC DISEASES | 2003年 / 62卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：353 / 353

页数：1

共 50 条

[1] Cost effectiveness analysis of etanercept (ENBREL) versus infliximab (Remicade) in the treatment of rheumatoid arthritis patients.
Malone, DC
Ortmeier, BG
[J]. ARTHRITIS AND RHEUMATISM, 2002, 46 (09): : S95 - S95
[2] Cost-effectiveness analysis of etanercept versus infliximab and anakinra in the treatment of rheumatoid arthritis in italy.
Leardini, G
Ganguly, R
Singh, A
[J]. ARTHRITIS AND RHEUMATISM, 2003, 48 (09): : S460 - S461
[3] COST-EFFECTIVENESS ANALYSIS OF ETANERCEPT AND INFLIXIMAB IN THE TREATMENT OF RHEUMATOID ARTHRITIS (RA) IN SPAIN
Guijarro, P.
Crespo, C.
Brosa, M.
[J]. VALUE IN HEALTH, 2012, 15 (07) : A448 - A448
[4] Cost-effectiveness analysis of etanercept monotherapy versus infliximab plus methotrexate in the treatment of rheumatoid arthritis.
Malone, DC
[J]. ARTHRITIS AND RHEUMATISM, 2001, 44 (09): : S322 - S322
[5] Relative cost of etanercept versus infliximab in the treatment of rheumatoid arthritis.
Sweis, BP
Ellman, CJ
[J]. ARTHRITIS AND RHEUMATISM, 2004, 50 (09): : S44 - S44
[6] Cost-effectiveness analysis of etanercept vs infliximab for treatment of severe rheumatoid arthritis in Brazil
Saggia, M. G.
Pina, F. P.
[J]. VALUE IN HEALTH, 2006, 9 (06) : A220 - A220
[7] The cost-effectiveness of etanercept and infliximab for the treatment of patients with psoriatic arthritis
Vergel, Y. Bravo
Hawkins, N. S.
Claxton, K.
Asseburg, C.
Palmer, S.
Woolacott, N.
Bruce, I. N.
Sculpher, M. J.
[J]. RHEUMATOLOGY, 2007, 46 (11) : 1729 - 1735
[8] Cost-Effectiveness Analysis of Biopharmaceuticals for Treating Rheumatoid Arthritis: Infliximab, Adalimumab, and Etanercept
Gholami, Ahmad
Azizpoor, Jassem
Aflaki, Elham
Rezaee, Mehdi
Keshavarz, Khosro
[J]. BIOMED RESEARCH INTERNATIONAL, 2021, 2021
[9] COST-EFFECTIVENESS ANALYSIS OF TOCILIZUMAB VERSUS INFLIXIMAB FOR THE PATIENTS WITH RHEUMATOID ARTHRITIS IN KAZAKHSTAN
Bektur, C.
Kayir, F.
Nurgozhin, T.
[J]. VALUE IN HEALTH, 2014, 17 (07) : A379 - A379
[10] COST-EFFECTIVENESS ANALYSIS OF ETANERCEPT IN THE TREATMENT OF RHEUMATOID ARTHRITIS IN CHINA
Zhang, Y.
Yang, L.
Dong, P.
Xie, X.
Tang, B.
[J]. VALUE IN HEALTH, 2012, 15 (07) : A673 - A673

← 1 2 3 4 5 →